Ionis Pharmaceuticals (Ionis Pharmaceuticals) Total Liabilities : $2,603.4 Mil (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Total Liabilities?

Ionis Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was $2,603.4 Mil.

Ionis Pharmaceuticals's quarterly Total Liabilities increased from Jun. 2023 ($2,542.83 Mil) to Sep. 2023 ($2,618.51 Mil) but then declined from Sep. 2023 ($2,618.51 Mil) to Dec. 2023 ($2,603.39 Mil).

Ionis Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 ($1,839.95 Mil) to Dec. 2022 ($1,960.99 Mil) and increased from Dec. 2022 ($1,960.99 Mil) to Dec. 2023 ($2,603.39 Mil).

Ionis Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Ionis Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Total Liabilities Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,548.57

1,646.47

1,839.95

1,960.99

2,603.39

Ionis Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															1,960.99	2,398.65	2,542.83	2,618.51	2,603.39

Ionis Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ionis Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	448.09	+	(1400.376	+	513.736
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	241.184	+	0)
	=	2,603.4

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2990.072	-	386.686
	=	2,603.4

Ionis Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	448.09	+	(1400.376	+	513.736
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	241.184	+	0)
	=	2,603.4

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	2990.072	-	386.686
	=	2,603.4

Ionis Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (NAS:IONS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

IONS:Mexico ISI:Germany ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionispharma.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Executives

Brian Birchler	officer: EVP, Corp and Development Ops	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Patrick R. O'neil	officer: SVP, Legal and General Counsel	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Onaiza Cadoret-manier	officer: Chief Corp Dev and Cml Officer	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eugene Schneider	officer: EVP, Chf Clinical Develop Offc	C/O IONIS PHARMACEUTICALS, 2855 GAZELLE CT, CARLSBAD CA 92010
Joseph Baroldi	officer: Chief Business Officer	C/O IONIS PHARMACEUTICALS, INC., C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eric Swayze	officer: SVP, Research	2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Brett P Monia	director, officer: Senior Vice President	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Richard S Geary	officer: Senior Vice President	2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Elizabeth L Hougen	officer: SVP, Finance and CFO	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
C Frank Bennett	officer: Vice President	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
B Lynne Parshall	director, officer: Executive Vice President, CFO	2855 GAZELLE COURT, CARLSBAD CA 92010
Joseph Iii Klein	director	C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Allene M. Diaz	director	C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Spencer R Berthelsen	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Frederick T Muto	director	2855 GAZELLE COURT, CARLSBAD CA 92010